viewAdmedus Ltd

Admedus advances in North America with more products and markets on the horizon

Wayne Paterson, chief executive of Admedus Ltd (ASX:AHZ), speaks about flagship ADAPT tissue products securing regulatory approval in Canada and a distribution network in the U.S..

Paterson also details landmark progress for the Admedus transcatheter aortic valve replacement (TAVR) device prototype.

“The key for Admedus is that we developed our portfolio in a way that makes us unique and creates an unassailable moat around the company… The company is pivoting towards 3D moulded surgical solutions… When you mould the clinical benefits as well as our ability to shape these products, we are in a very unique space.”

A further 16 projects covering many aspects of surgery are in the development pipeline, with releases expected later this year, and new global markets set to open up pending regulatory approvals.

Quick facts: Admedus Ltd

Price: 4.48 AUD

Market: ASX
Market Cap: $26.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...



Admedus Ltd proud to unveil its valves publicly for the first time in London

Admedus Ltd's (ASX:AHZ) CEO Wayne Paterson caught up with Proactive's Andrew Scott while in London. The firm recently made what's been described as a transformational move to sell off its CardioCel® and VascuCel® patch business. Paterson says the focus is now firmly on the Adapt...

on 20/11/19

2 min read